콘텐츠로 건너뛰기
Merck
  • Cardiac-peripheral transvenous gradients of microRNA expression in systolic heart failure patients.

Cardiac-peripheral transvenous gradients of microRNA expression in systolic heart failure patients.

ESC heart failure (2020-04-08)
Inbar Ben-Zvi, Natalia Volinsky, Liza Grosman-Rimon, Izhak Haviv, Guy Rozen, Nizar Andria, Nofar Asulin, Nufar Margalit, Ibrahim Marai, Offer Amir
초록

The aims of the study are to assess the levels of coronary sinus (CS) miRNAs of systolic heart failure (HF) patients in samples obtained during cardiac resynchronization therapy (CRT) device implantation and compare them to the peripheral systemic venous miRNA expression. The cardiac specific miRNA levels were assessed in 60 patients, 39 HF patients with reduced ejection fraction and 21 control patients. The levels of four cardiac specified miRNAs (miR-21-5p, miR-92b-3p, miR-125b-5p, and miR-133a-3p) were compared between the peripheral samples of HF and controls and between peripheral venous in CS in the HF groups. Compared with controls, HF patients had higher peripheral serum venous levels of miR-125b-5p and miR-133-3p. In the HF group, the levels of expression were higher for miR-125b-5p and lower for miR-92, and miR-21-5p in the CS, compared with the peripheral venous circulation. The differences in miRNA expressions in CS compared with those in the periphery suggest that changes that may occur at the levels of the myocardial tissue in HF may be more relevant to our understanding of the biological linkage between miRNA expression and HF, than the traditional analysis of systemic serum miRNA expression.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Tris-EDTA buffer solution, BioUltra, for molecular biology, pH 8.0